43 related articles for article (PubMed ID: 9858771)
1. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract][Full Text] [Related]
2. Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer.
Vazdar L; Gabrić ID; Kruljac I; Pintarić H; Šeparović R; Kirigin Biloš LS; Pavlović M; Tečić Vuger A; Štefanović M
Sci Rep; 2021 Jul; 11(1):14395. PubMed ID: 34257352
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.
Wali VB; Gilmore-Hebert M; Mamillapalli R; Haskins JW; Kurppa KJ; Elenius K; Booth CJ; Stern DF
Breast Cancer Res; 2014 Dec; 16(6):501. PubMed ID: 25516216
[TBL] [Abstract][Full Text] [Related]
4. Amplification and deletion of the RAPH1 gene in breast cancer patients.
Batistela MS; Boberg DR; Andrade FA; Pecharki M; de S F Ribeiro EM; Cavalli IJ; Lima RS; Urban CA; Furtado-Alle L; Souza RL
Mol Biol Rep; 2013 Dec; 40(12):6613-7. PubMed ID: 24057252
[TBL] [Abstract][Full Text] [Related]
5. Role of traditional and new biomarkers in breast carcinogenesis.
Macis D; Cazzaniga M; De Censi A; Bonanni B
Ecancermedicalscience; 2009; 3():157. PubMed ID: 22276018
[TBL] [Abstract][Full Text] [Related]
6. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.
Rosen LS; Ashurst HL; Chap L
Oncologist; 2010; 15(3):216-35. PubMed ID: 20200040
[TBL] [Abstract][Full Text] [Related]
7. Role of ErbB4 in breast cancer.
Sundvall M; Iljin K; Kilpinen S; Sara H; Kallioniemi OP; Elenius K
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):259-68. PubMed ID: 18454307
[TBL] [Abstract][Full Text] [Related]
8. ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition.
Muraoka-Cook RS; Feng SM; Strunk KE; Earp HS
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):235-46. PubMed ID: 18437540
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
Sassen A; Rochon J; Wild P; Hartmann A; Hofstaedter F; Schwarz S; Brockhoff G
Breast Cancer Res; 2008; 10(1):R2. PubMed ID: 18182100
[TBL] [Abstract][Full Text] [Related]
10. Gene copy numbers of HER family in breast cancer.
Zaczek A; Wełnicka-Jaśkiewicz M; Bielawski KP; Jaśkiewicz J; Badzio A; Olszewski W; Rhone P; Jassem J
J Cancer Res Clin Oncol; 2008 Feb; 134(2):271-9. PubMed ID: 17661082
[TBL] [Abstract][Full Text] [Related]
11. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.
Muraoka-Cook RS; Caskey LS; Sandahl MA; Hunter DM; Husted C; Strunk KE; Sartor CI; Rearick WA; McCall W; Sgagias MK; Cowan KH; Earp HS
Mol Cell Biol; 2006 Sep; 26(17):6412-24. PubMed ID: 16914727
[TBL] [Abstract][Full Text] [Related]
12. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.
Abd El-Rehim DM; Pinder SE; Paish CE; Bell JA; Rampaul RS; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
Br J Cancer; 2004 Oct; 91(8):1532-42. PubMed ID: 15480434
[TBL] [Abstract][Full Text] [Related]
13. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer.
Schlotter CM; Vogt U; Bosse U; Mersch B; Wassmann K
Breast Cancer Res; 2003; 5(2):R30-6. PubMed ID: 12631396
[TBL] [Abstract][Full Text] [Related]
14. ErbB-4: a receptor tyrosine kinase.
Zhou W; Carpenter G
Inflamm Res; 2002 Feb; 51(2):91-101. PubMed ID: 11926320
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.
Stern DF
Breast Cancer Res; 2000; 2(3):176-83. PubMed ID: 11250707
[TBL] [Abstract][Full Text] [Related]
16. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction.
Lehmann U; Glöckner S; Kleeberger W; von Wasielewski HF; Kreipe H
Am J Pathol; 2000 Jun; 156(6):1855-64. PubMed ID: 10854209
[TBL] [Abstract][Full Text] [Related]
17. Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer.
Vogt U; Bielawski K; Schlotter CM; Bosse U; Falkiewicz B; Podhajska AJ
Gene; 1998 Nov; 223(1-2):375-80. PubMed ID: 9858771
[TBL] [Abstract][Full Text] [Related]
18. Critical determination of the frequency of c-erbB-2 amplification in breast cancer.
Hubbard AL; Doris CP; Thompson AM; Chetty U; Anderson TJ
Br J Cancer; 1994 Sep; 70(3):434-9. PubMed ID: 7915911
[TBL] [Abstract][Full Text] [Related]
19. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.
Erdogan S; Ergin M; Tuncer I
Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
